Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472350 | 0.87 | MET (0.59) | METAXLKDR | |
| SCHEMBL4482808 | 0.84 | MAPK1 (0.59) | METMAPK1HTTSYKMAPT | |
| SCHEMBL1472345 | 0.79 | AXL (0.53) | METAXLKDR | |
| SCHEMBL1472526 | 0.75 | AXL (0.54) | METHTTMAPTLMNAAXL | |
| SCHEMBL1472307 | 0.75 | AXL (0.52) | METAXLKDRBRAF | |
| SCHEMBL13860798 | 0.74 | AXL (0.56) | METAXLKDRBRAF | |
| SCHEMBL13816015 | 0.74 | MET (0.62) | METMAPK1HTTMAPTLMNA | |
| SCHEMBL198372 | 0.73 | AXL (0.53) | METAXLKDRBRAF | |
| SCHEMBL4330366 | 0.73 | MET (0.65) | METAXLKDRBRAF | |
| SCHEMBL1472392 | 0.73 | MET (0.62) | METMAPK1MAPTAXLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2125780-B1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915287-B2 | Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide | AMGEN INC. (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2125780-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200464-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079294-A1 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200464-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | MET 3/4885MAPK1 1954/4885HTT 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.